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Background: Leishmaniasis,a broad spectrum of diseases caused by several sister species of protozoa belonging to
family trypanosomatidae and genus leishmania , generally affects poorer sections of the populace in third world
countries. With the emergence of strains resistant to traditional therapies and the high cost of second line drugs
which generally have severe side effects, it becomes imperative to continue the search for alternative drugs to
combat the disease. In this work, the leishmanial genomes and the human genome have been compared to
identify proteins unique to the parasite and whose structures (or those of close homologues) are available in the
Protein Data Bank. Subsequent to the prioritization of these proteins (based on their essentiality, virulence factor
etc.), inhibitors have been identified for a subset of these prospective drug targets by means of an exhaustive
literature survey. A set of three dimensional protein-ligand complexes have been assembled from the list of
leishmanial drug targets by culling structures from the Protein Data Bank or by means of template based homology
modeling followed by ligand docking with the GOLD software. Based on these complexes several structure based
pharmacophores have been designed and used to search for alternative inhibitors in the ZINC database.
Result: This process led to a list of prospective compounds which could serve as potential antileishmanials. These
small molecules were also used to search the Drug Bank to identify prospective lead compounds already in use as
approved drugs. Interestingly, paromomycin which is currently being used as an antileishmanial drug
spontaneously appeared in the list, probably giving added confidence to the ‘scaffold hopping’ computational
procedures adopted in this work.
Conclusions: The report thus provides the basis to experimentally verify several lead compounds for their
predicted antileishmanial activity and includes several useful data bases of prospective drug targets in leishmania,
their inhibitors and protein – inhibitor three dimensional complexes.
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Leishmaniasis, a broad spectrum of diseases, is caused
by more than 20 sister species of protozoa belonging to
the family Trypanosomatidae and genus Leishmania.
These diseases are generally classified into three forms:
visceral (VL), cutaneous (CL) and mucocutaneous (MCL),
of which VL is lethal if left untreated, whereas CL, MCL
generally self cure, though with the possibility of leaving
permanent scars on the patient. The Indian subcontinent
along with Sudan and Brazil account for the overwhelming* Correspondence: rahul.banerjee@saha.ac.in
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unless otherwise stated.majority of cases in VL, while the incidence of CL pre-
dominantly occurs in Afghanistan, Algeria, Brazil, Iran,
Peru, Saudi Arabia and Syria [1]. Overall, about 10 million
people are affected worldwide. The vector for this disease
is the phlebotominae sand fly, which injects the parasites
into the host in the course of a blood meal. The parasites
thus exist in two forms: as mobile, flagellated pro-
mastigotes in the gut of the sandfly and non-motile,
non-flagellated amastigotes which multiply within the
phagolysosomal compartment of the macrophage in
the mammalian host [2].
The first line of defense against the parasites traditionally
continues to be generic pentavalent antimonials (sodium
stibogluconate), especially in those regions where resistant
strains have yet to appear. With the emergence of strainsLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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[3-5] second line drugs such as amphotericin-B (along
with its liposomal formulations) and miltefosine are being
extensively used [6]. However, both these drugs are more
expensive than antimonials, toxic with reportedly severe
side effects. Pentamidine and paromomycin are other
drugs currently in use though their ready availability in
endemic areas appears to be limited [7]. It is thus clear
that there is an urgent need to search for and identify
therapeutic alternatives to combat the disease.
With the availability of full genome sequences, search
for drug targets in pathogenic organisms have been greatly
facilitated. Comparative genomics allows the identification
of genes unique to an organism, determination of parasitic
genes absent in human and the evolutionary conservation
of genes, probably reflecting upon their essentiality [8].
Gene conservation across pathogenic species also gives
the added advantage that a single broad based antipara-
sitic targeting a conserved protein, could be used as a drug
for several ailments. The genomes of five leishmanial
species L. major, L. infantum, L. donovani , L. mexicana
and L. braziliensis have been sequenced; with the first three
consisting 36 chromosomes each, while L. braziliensis
contains only 35. Notably, L. braziliensis has been assigned
to a different subgenus Leishmania (Viannia) sp. and is
thus somewhat distantly related to the others, which
belong to the subgenus Leishmania (Leishmania) sp.. This
reduction in chromosome number in L. braziliensis is due
to a fusion event joining chromosome 20 and 34 (as
numbered in L. major). Likewise, L. mexicana is two
chromosomes less due to two fusions between four chro-
mosomes (chromosome 8 and 29; chromosome 20 and
36). These genomes have approximately 8300 protein
coding regions of which only about 40% can be ascribed a
putative function [9-11]. In addition, the genomes of T.
brucei (11 chromosomes) and T. cruzi are also available.
Generally , the genomes of kinetoplastidae exhibit a high
degree of synteny (conservation of gene order) in the
organization of their genomes [12]. Comparison between
the genomes of T. brucei, T. cruzi and L. major revealed a
conserved core of approximately 6200 trypanosomatid
genes and about 1000 ORFs [11] were notable for their
presence in the genome of L. major alone. Further, upon
comparing the genomes of leishmanial species, 5, 26 and
47 genes were identified to be exclusively and specifically
present in the genomes of L. major , L. infantum and L.
braziliensis respectively [13].
Leishmanial genomes consist of several novel metabolic
pathways whose enzymes could serve as potential drug
targets. Some of the distinctive features of these genomes
include the presence of atypical protein kinases lacking
the SH2, SH3, FN-III and immunoglobulin like domains
which occur most frequently in humans [14,15]. The
cellular surface of leishmania consists of several uniqueglycoproteins which are essential for immune evasion
and host – parasite interaction. The most abundant of
these glycoproteins are attached to the surface of the
plasma membrane via GPI (glucosylphosphatidyl inositol)
anchors, which are essential for parasitic survival. Other
novel pathways involve trypanothione metabolism, essen-
tial for cell growth and differentiation, which is replaced
by glutathione in humans. The first enzyme in trypa-
nothione synthesis is the enzyme ornithine decarboxylase
targeted by the drug diflouromethyl ornithine, prescribed
for human sleeping sickness. Enzymes of the glycolytic
pathway, ergosterol synthesis in sterol metabolism and the
purine salvage pathway also offer potential drug targets
for therapeutic intervention [14]. Some of these pathways
will be discussed in greater detail in the later sections of
this paper.
Due to the exponential increase in genomic information,
researchers are now confronted with a rapidly expanded
list of gene products from which to select prospective
targets. Several scoring schemes have been proposed
which surveys the genome of a pathogenic organism and
ranks genes according to their potential as drug targets
[8,16,17]. Most schemes give a high weightage to the
essentiality of the protein in the life cycle of the parasite,
conservation of the target among different sister species
and its corresponding absence in humans. Experimentally,
either the lethality of gene deletion or insertion of trans-
posons into the selected gene has been used to determine
its essentiality. Non-essential genes could also be selected
as targets, provided they play a vital role in the infective
virulence of the pathogens. Other considerations includes
the assayability of the protein, expression level during
the life cycle of the organism possibly determined by
microarray data and computational flux based analysis
to gauge the effect of protein inhibition on the integrity
of biochemical networks. In this connection, the TDR-
target database is one of the most well cited amongst
such databases [16]. This database consists of an exhaust-
ive list of drug targets from the genomes of L. major, T.
brucei, M. leprae and a host of other pathogens respon-
sible for neglected tropical diseases. A useful feature of
the database is its ability to prioritize a set of drug targets,
where each criterion is assigned a weight and there is
flexibility to change the weights associated with different
factors (pathogenicity, essentiality, etc.) in the scoring
scheme to extract a ‘custom-made’ list of targets relevant
to the research interest of the user.
Several crystal structures of trypanosomal proteins, either
individually or complexed with inhibitors are currently
available in the Protein Data Bank, such as trypanothione
reductase (T. brucei), trypanothione synthetase (L. major),
pteridine reductase 1 (L. major), nucleoside hydrolase
(T. vivax) and ATP dependent phosphofructokinase
(T. brucei), which provide a detailed three dimensional
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specific inhibitors. In order to generate a library of pro-
spective ligands which could have high affinities towards
the active sites of targeted proteins, drug databases could
be searched with structure based pharmacophores derived
from protein ligand complexes. ‘Scaffold hopping’ or
‘chemotype switching’ [18-20], which involves identify-
ing molecules with dissimilar backbone structures yet
exhibiting very similar pharmacological properties, is
one of the widely used techniques to generate compound
libraries for eventual screening [21-25]. Lately, consider-
able success has been achieved in the application of struc-
ture based pharmacophores in the identification of lead
compounds [21-25]. In the current work the human and
the L. major genome have been compared to identify a set
of proteins unique to the parasite. Crystal structures of
these proteins or those of closely related homologues have
been extracted from the Protein Data Bank (PDB) and the
literature has been extensively surveyed to identify their
specific high affinity inhibitors. Crystal structures of the
protein (target) - inhibitor complexes have then been uti-
lized to generate structure based pharmacophores. In case
the crystal structures of the ligand bound targets were not
available in the PDB, the inhibitors were computationally
docked into the active sites of their receptors. Finally, the
ZINC database and Drug Bank has been searched utilizing
this set of pharmacophores to generate a set of com-
pounds which could serve as a library in the search for
prospective antileishmanial drugs.
Methods
The annotated coding sequences (CDS) from the ge-
nomes of L. major (8316 CDS), L. donovani (8032 CDS),
L. mexicana (8249 CDS), L. braziliensis (8056 CDS), L.
infantum (8227 CDS), T. brucei (9962 CDS) and human
(~41961 CDS) were downloaded from the NCBI genome
database (http://www.ncbi.nlm.nih.gov/genome/; updated
as on September 1, 2013). The standalone BLAST [26]
was obtained from the NCBI ftp server (ftp://ftp.ncbi.nlm.
nih.gov/blast/executables/blast+/LATEST/). Here BLAST
refers to the BLASTp program of the NCBI standalone
BLAST package which aligns protein amino acid se-
quences. To compare the annotated protein sequences
between human and L. major(CDS’s) , the CDS’s from
L. major were first fed in as a query (in FASTA format)
whereas the human CDS’s were processed in the make-
blastdb tool to form a BLAST database. This was followed
by a second run of BLAST (with identical parameters) in
which the human sequences were considered to be ‘query’
and the L. major proteins the database. Proteins which
simultaneously passed identical filters in both the runs of
BLAST were considered for the second step in the pipe-
line. A sole exception was made in the case of ATP
dependent phosphofructokinase (PFK) in the first filter asthe possibility of PFK being a drug target for trypanoso-
matids has been mentioned in the literature [27-29]. To
compare L. major CDS’s with those of closest – related
species, L. major proteins were fed in as a query and se-
quences from the other genome were made the database.
All alignments with an E-value less than one were output
from the program and default options were used for all
other parameters. The software to analyze the BLAST
outputs was developed locally in C/C++, Perl and the final
results were displayed on Microsoft Excel sheets for
further analysis.
In order to identify the unique metabolome in L.
major with respect to its human host the ‘Comparative
Analysis and Statistics’ option in the BioCyc Database
(http://www.biocyc.org/) was used [30]. The metabolic
pathways and enzymes associated with this unique set
of metabolites from L.major were manually culled from
the LeishCyc database (http://biocyc.org/LEISH/organ-
ism-summary?object=LEISH).
Template based homology modeling was performed
using the MODELLER software both in the standalone
mode and also implemented in Accelrys Discovery Studio
2.5. In addition, the GUI version of Modeller 9.11v (Easy
Modeller 4.0) [31] was also used.
GOLD 5.2 (http://www.ccdc.cam.ac.uk/Solutions/Gold-
Suite/Pages/GOLD.aspx) was used to dock specific ligands
onto the active site of their corresponding enzymes with
the following parameters: population size 100, selection
pressure 1.1, number of operations 100000(min) - 125000
(max), islands 5, niche size 2, crossover frequency 95,
mutation frequency 95, migration frequency 10 and
search efficiency 100%. The program was run at least
10 times in order to confirm the best docking solution
which was identified based on three criteria a) the
CHEMPLP score b) rmsd between the docked solution
and the initial placement of the ligand and c) visual
survey and examination of the contacts between the
docked ligand and protein. In case sufficient prior infor-
mation was already available with regard to the position
of the ligand in the active site of the protein (such as in
Group B : See Section on The Protein – Ligand Com-
plexes), the docking solution with the minimum rmsd
(generally less than 1.0 Å) and whose CHEMPLP score
was amongst the top three (comparable to the score
derived from the original protein – ligand complex
available in the PDB), was accepted as the most reasonable
solution, subsequent to the visual inspection of the ligand
bound active site. In cases where such information was
either ambiguous or limited (Group C : See Section on
The Protein – Ligand Complexes) the threshold on rmsd
was relaxed to about 2.0 - 2.75 Å, the interactions of the
ligand with active site were visually examined and the
solutions grouped into sets with similar geometry with
respect to the binding site. Amongst these sets, the pose
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interactions and the best CHEMPLP score was accepted
as the most favoured solution. All solutions which
exhibited significant displacement of the ligand from
the putative active site of the protein (>3.75 Å) were not
considered. The decisions regarding both ligand flexibility
and the flexibility of residues constituting the active
site were decided on a case by case basis which will be
discussed below (in the Results and Discussion section).
Generally, in case the protein-ligand complex was avail-
able in the Protein Data Bank (PDB) and the leishmanial
protein modeled utilizing the molecule from such a
complex as a template, the ligand was transferred onto
the modeled protein by utilizing the rotation matrix,
translation vector derived from the superposition of the
modeled protein to the template (Dali Server; http://
ekhidna.biocenter.helsinki.fi/dali_lite/start) [32]. Most often
in such instances both the ligand and the active site were
held rigid whilst docking with GOLD. For ligands, whose
complexes with the targeted protein (from L. major) or its
close homologue were not available in the PDB, the ligand
coordinates were derived from its closest related structure
(as found as a complex in the PDB) by fourth atom fixing
techniques and energy minimized by the semi-empirical
quantum mechanical method in the program GAMESS
[33,34]. It goes without saying that the protein in such a
complex would either be the target (L. major) or a close
homologue from a sister trypanosomatid species. With
the initial placement of ligand into the protein active site
using the same techniques mentioned above, the newly
added chemical groups to the parent compound (obtained
from the PDB) were rendered flexible in the subsequent
docking by GOLD, in addition to selected active site resi-
dues which could provide steric hindrance in the docking
process. These residues were identified by visual examin-
ation of the initial docked position and examination of the
list of contacts. In GAMESS the self-consistent field wave
function with the semi-empirical basis set (AM1 model
Hamiltonian) was used and the optimum tolerance of the
energy minimization cycle was set to 1.0e-5. Where no in-
formation was available with regard to the association of
the ligand with the target protein, blind docking was
attempted subsequent to the placement of the ligand at
the centroid of the putative active site of the enzyme.
LigandScout version 3.12 (build 20130912) was used
to generate the structure based pharmacophores from
the crystallographic and modeled/docked complexes,
with manual monitoring of the entire process at every
stage. To validate the pharmacophores, the ligand along
with other active compounds (with relatively less IC50
values though with similar structures) were made the
kernel of a database which also included decoys gener-
ated from the D.U.D.E. decoy generator (http://dude.
docking.org/generate). The specific ligand, along withother actives and decoys were next submitted to
OMEGA 2.5.1.4 [35] to generate two conformers per
decoy and each of the active molecules from the
docked/crystal structures. Thus, the database for each
ligand (inclusive of the other actives and decoys) consisted
of about 1800 molecular conformers in all. The library
generating tool of LigandScout was then utilized to con-
vert the database into a library (*.ldb format), prior to
searching the library with the corresponding pharmaco-
phore. Invariably, the specific ligand used to derive the
structure based pharmacophore would be detected at the
topmost rank. Every validation database was split into
two, one consisting of actives and the other of decoys.
Ligand screening option in LigandScout was then invoked
to search both the databases with the specific pharmaco-
phore as the query (with the advanced options, scoring
function: ‘Pharmacophore - Fit’; Screening Mode: ‘Match
all query features’; Retrieval Mode: ‘Get best matching
conformation’).For every case, the maximum number of
omitted features were varied to get optimal results and
the ROC curve. Those pharmacophore queries, which
gave screening results with area under the ROC curve
less than 0.75 were not utilized in subsequent calculations.
Finally, the ZINC database was searched by all the struc-
ture based pharmacophores derived from the protein
ligand complexes.
Results and discussion
Comparative genomics – human versus Leishmania
The whole set of annotated protein-coding genes from
L. major genome (8316 CDS) was compared against the
ones from human genome (41961 CDS) and those para-
sitic proteins (4991 among 8316 sequences) which could
not align with any human gene, (first filter) with pident
(percentage sequence identity) >35% and a simultaneous
query coverage >50%, in two way reciprocal BLAST
runs with L. major as query, human as database and vice
versa (Materials & Methods), were selected for the next
filter. Hypothetical sequences (4407 CDS) were removed
from this list (second filter) and the Protein Databank
(PDB) searched for each of the remaining sequences,
which amounted to a total of 584 putative sequences. The
PDB database was downloaded from the RCSB-PDB
(http://www.rcsb.org/pdb/home/home.do) website and in-
corporated into BLAST using the methods given above
(Materials and Methods). Only those genes were selected
for subsequent analysis (a total 90 sequences) which re-
corded hits in the PDB with >40% sequence identity and a
simultaneous query coverage >75% (third filter). Each
gene from this set (consisting of L. major proteins alone)
were then checked for BLAST hits (pident >40% & query
coverage >75%) in the genomes of L. donovani, L. mexi-
cana, L. braziliensis, L. infantum and also in the clusters
of orthologous proteins in the Tritryp database (based on
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of data, only those (L. major) proteins with homologues/
BLAST hits in all the five genomes were retained (fourth
filter). The final set of genes consisted of a total of 86
polypeptide chains (Additional file 1). The schematic
representation of the successive filters to arrive final list
of drug targets is described in Figure 1. The separated
list of hypothetical sequences (4407 CDS) were independ-
ently searched in the PDB and eighteen sequences scored
hits satisfying the above criteria (given in Additional file 2).
Upon the application of more stringent criteria (pident >25
and query coverage >33) in the first filter, 47 out of the ori-
ginal 86 genes satisfied the new threshold values, of which
13 genes were retained from the first thirty proteins of the
original set (Additional file 1).
Target prioritization
This list of parasitic proteins were then sorted according
to a “weighted union” scoring scheme based on the fol-
lowing factors: i) essentiality as determined from experi-
mental studies, ii) virulence factor iii) expression profile
and iv) whether the natural substrate to the protein is a
ligand unique to Leishmania spp. with respect to human.
Information regarding essentiality and virulence were
obtained by an extensive literature survey, in addition toFigure 1 Schematic representation of steps involved in the selection
The separated set of hypothetical proteins were independently searched aconsulting the TDR database. A list of metabolites unique
to Leishmania spp. were identified by searching the
leishmanial and human metabolome databases [37].
The metabolome of L. major was obtained from the
Biocyc Database (http://biocyc.org/LEISH/class-tree?
object=Compounds) (see Method) and the correspond-
ing metabolome from human was available in the Human
Metabolome database (HumanCyc; http://biocyc.org/
HUMAN/organism-summary?object=HUMAN). Util-
izing bioinformatics tools available in the Biocyc, the
two metabolomes were compared and the ligands unique
to Leishmania spp. were filtered out. From this compari-
son 129 metabolites were identified to be unique to the
parasite. The full set of enzymes corresponding to these
substrates were assembled into a blast database and run
against the initial list of 86 genes. Only eight polypeptide
chains from this list of 86 proteins were found to be as-
sociated with unique ligands. As has been mentioned
previously, leishmania has two stages in its life cycle
(amastigote and promastigote) and the information
whether the gene was ‘constitutively expressed’ in both
stages or in only one of them was obtained primarily
from GeneDB [38], which provides a convenient plat-
form to cull information with regard to leishmanial
gene expression from the work of Leifsko et al. [39]. Aof drug targets from the genome of L. major (Additional file 1).
gainst the PDB (Additional file 2).
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one of the criteria given above and thus the highest
possible score obtained by any protein could be 400.
Targets lacking experimental data with regard to essen-
tiality were still given 50 in case strong arguments
existed in favour of their being essential genes (e.g.
phosphofructokinase in the glycolytic pathway) and 20
if the protein was found to be indispensable in a sister
species. A score of 100 was assigned to the gene which
was constitutively expressed in both stages and 50 if
expressed in only one of them. The final list of prioritized
proteins are given in (Additional file 1) and the first thirty
proteins from this list (Table 1) are described in some
detail in the context of unique metabolic pathways of
leishmania parasites. The only available information with
regard to the 18 hypothetical proteins (Additional file 2)
was that they are constitutively expressed in both
stages of the leishmanial life cycle [39] , and thus upon
prioritization, these proteins (all with an identical score of
100) did not find their place amongst the first thirty, in
the list of annotated proteins (given in Table 1).
As expected, prominent amongst the list of prioritized
proteins (Table 1) are three enzymes associated with try-
panothione i)trypanothione reductase (TR: 1), ii)putative
trypanothione synthetase (TS: 3) and iii)trypanothione -
dependent glyoxalase I (GLO1: 10). The trypanothione
system in leishmania which replaces the ubiquitous
glutathione system present in humans, enables the para-
site to survive the high oxidative stress found in the host
immune system and the presence of toxic heavy metals
[40]. Both trypanothione synthetase (which synthesizes
trypanothione from glutathione and spermidine) and try-
panothione reductase (which keeps it in its reduced form
in the presence of NADPH) are attractive drug targets
[41], as this system is the only pathway involved in the
crucial regulation of oxidative stress in the parasites.
Reduced trypanothione in turn causes the reduction of
tryparedoxin which then transfers electrons to the re-
cycling enzyme tryparedoxin peroxidase [40]. Although
TR and human glutathione reductase(GR) exhibits 35%
sequence identity and shares many physicochemical
properties , yet their corresponding active sites are dif-
ferent due to their diverse substrate specificities [42];
TR binding only to the oxidized forms of positively
charged glutathionyl – polyamine conjugates whereas
human GR associates only with negatively charged
glutathione [43]. The difference in specificity is primarily
due to the presence of five amino acid residues in the TR
active site, which confers enhanced hydrophobicity, nega-
tive charge and wider access to its binding pocket relative
to human GR [43]. Several inhibitors specifically designed
for TR have yet to be entirely successful as drugs, probably
due to the wide active site of the enzyme which poses
obstacles for structure-based drug design, coupled to thepharmacokinetic properties of the inhibitors [43]. In
addition, trypanothione is also implicated in the Glyoxalase
I, II systems in the parasite (again replacing glutathione
in humans) which is responsible for the removal of toxic
and mutagenic methylglyoxal formed as a byproduct of
glycolysis. The crystal structure of leishmanial glyoxalase I
(GLO I) reveals differences with respect to the corre-
sponding human enzyme in its active site architecture
[44], which includes increased negative charge and hydro-
phobicity along with the truncation of a loop which could
be involved in the catalytic activity of the human enzyme.
The surface glycocalyx of Leishmania spp. consists of
several unique sugars and glycoconjugates which mediate
host – parasite interaction and virulence. A significant
fraction of these glycoconjugates consists of lipophospho-
glycans (LPG) implicated in the adhesion of leishmania
to the host cell and glycoinositolphospholipids (GIPLs)
involved in pathogenesis [45]. Both LPGs and GIPLs,
have β-galactofuranose (β-Galf ) as one of their main
constituents, an unusual sugar not found in vertebrates.
Three proteins in (Table 1), UDP-galactopyranose mutase
(UGM: 4), putative UDP-Glc 4′-epimerase (galE: 5), UDP-
sugar pyrophosphorylase (USP: 26) are constituents of
biochemical pathways, either directly or indirectly respon-
sible for the synthesis of β–Galf. β – Galf is synthesized
from its precursor UDP-galactose (UDP–Gal) by the en-
zyme UDP-galactopyranose mutase (UGM), inhibition of
which is known to regulate parasitic virulence and hence
is an attractive target [46]. The cellular pool of UDP-Gal is
contributed by the Isselbacher and Leloir pathways
[45,46]. In the Leloir pathway, UDP–Gal is synthesized
from galactose - 1 - phosphate by UDP - sugar pyrophos-
phorylase (USP), whereas in the Isselbacher pathway
galactose–1–phosphate is converted to UDP-Gal and
glucose–1-phosphate by galactose–1–phosphate uri-
dyltransferase. Within this pathway, the reversible and
bidirectional enzyme UDP-Glc 4′-epimerase (GalE) can
convert UDP – Gal to UDP – Glucose and vice versa.
Despite low sequence identity of about 33% between hu-
man and parasitic GalE , high resolution crystal structures
of both proteins reveal a common overall topology and
similar protein-ligand interactions at the active site [47].
GalE holds great promise as a drug target in T. brucei.
Next, a set of five proteins implicated in purine/pyrimi-
dine metabolism occupied fairly prominent positions in
Table 1: putative deoxyuridine triphosphatase nucleotido-
hydrolase (dUTPase: 11), nonspecific nucleoside hydrolase
(NNH: 24), and putative OMPDCase – OPRTase
(OMPDC-OPRT: 29). Unlike their human and other
mammalian hosts leishmania lack the molecular machin-
ery to synthesize purine nucleotides de novo and is thus
dependent on a purine salvage pathway [48]. Extensive
genetic studies on the purine salvage pathway show it
to be highly complex with several redundant links. For
Table 1 Drug targets from the genome of L. major
No. Target proteins Metabolic pathway Gene name (genedb id) Unique ligand Prioritization score
1 Trypanothione reductase Trypanothione metabolism LmjF05.0350 Trypanothione 400




3 Putative trypanothione synthetase Trypanothione metabolism LmjF27.1870 Trypanothione 350
4 UDP-galactopyranose mutase Sugar metabolism LmjF18.0200 β-D-ribopyranose 350
5 Putative udp-glc 4′-epimerase Sugar Metabolism LmjF33.2300 Absent 300
6 Inhibitor of cysteine peptidase Peptidase/protease LmjF24.1770 Absent 220
7 Peptidase m20/m25/m40 family-like protein Peptidase/protease LmjF31.1890 Absent 220
8 Putative endoribonuclease L-PSP (pb5) RNase LmjF23.0200 Absent 220
9 Putative peptidase M20/M25/M40 Peptidase/protease Lmjf33.1610 Absent 220
10 Trypanothione-dependent glyoxalase I Trypanothione metabolism GLO1 S-lactoyl trypanothione 220
11 Putative deoxyuridine triphosphatase Purine/pyrimidine metabolism DUT Absent 200
12 Putative metacaspase protein Peptidase/protease LmjF35.1580 Absent 200
13a Macrophage migration inhibitory factor-like protein Host-parasite interaction, macrophage
migration inhibitory factor
MIF1 Absent 200
13b Macrophage migration inhibitory factor-like protein Host-parasite interaction, macrophage
migration inhibitory factor
MIF2 Absent 200
14 Putative calpain-like cysteine peptidase Peptidase/protease LmjF20.1185 Absent 200
15 Putative proteasome activator protein pa26 Peptidase/protease LmjF35.0750 Absent 200
16a Putative serine peptidase Peptidase/protease LmjF27.2630 Absent 200
16b Putative serine peptidase Peptidase/protease LmjF29.1270 Absent 200







Amino acid metabolism LmjF31.0010 5-methyltetrahydropteroyltri-L-glutamate 200
19 2,3-bisphosphoglycerate-independent
phosphoglycerate mutase
Glycolytic pathway PGAM Absent 150
20 ADF/Cofilin Cellular motility LmjF29.0510 Absent 150
21 ATP-dependent phosphofructokinase Glycolytic pathway LmjF29.2510 Absent 150
22 Glucokinase Glycolytic pathway LmjF36.2320 Absent 150
23 Glycerol-3-phosphate dehydrogenase
[NAD+],glycosomal
Glycerophospholipid metabolism GPD Absent 150
24 Nonspecific nucleoside hydrolase Purine/pyrimidine metabolism NH Absent 150




















Table 1 Drug targets from the genome of L. major (Continued)
26 UDP-sugar pyrophosphorylase Sugar metabolism USP Absent 150
27 Putative glutamate dehydrogenase Amino acid metabolism LmjF28.2910 Absent 120
28 Putative isocitrate dehydrogenase TCA cycle LmjF33.2550 Absent 120
29 Putative OMPDCase-OPRTase Pyrimidine metabolism LmjF16.0550 Absent 120
30 3-mercaptopyruvate sulfurtransferase Amino acid metabolism LmjF05.0970 Absent 120
Prioritized list of drug targets consisting of the first thirty proteins. Information regarding their metabolic pathway, genebank ID and association with a ligand unique to leishmania w.r.t human are also included in the
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key enzymes of the pathway: adenine phosphoribosyl
transferase (APRT), hypoxanthine – guanine phos-
phoribosyltransferase (HGPRT), adenosine kinase (AK)
and xanthine phosphoribosyl transferase (XPRT) were
all found to be viable [48]. However, the phenotypic
characterization of the double Δhgprt/Δxprt mutant
indicated that purine salvage from extracellular sources is
primarily funneled through XPRT, HGPRT with AK and
APRT being by and large superfluous [49]. Thus, the cen-
tral role played by these two enzymes (HGPRT & XPRT)
confers functional importance to downstream molecules
which distributes their products into adenylate and guany-
late nucleotides. Adenylosuccinate synthetase (ADSS) and
adenylosuccinate lyase (ASL) are two such enzymes which
sequentially convert IMP to AMP, the former catalyzing
the GTP dependent formation of adenylosuccinate from
IMP and aspartic acid while the latter removes a fumarate
from adenylosuccinate formed by ADSS. Knock out
mutants of ASL shows highly attenuated infectivity of
the parasites [49].
Null mutants of purine transporters LdNT1, LdNT2
(Δldnt1, Δldnt2 and Δldnt1 /Δldnt2) do not appear to
interfere with parasitic growth based on natural purine
sources (with the exception of xanthosine) [48]. Subse-
quently, the enzyme nonspecific nucleoside hydrolase
(NNH) was identified to perform the non-specific con-
version of purine nucleosides to nucleobases, which can
then be transported by other transporters LdNT3 and
LdNT4 [48]. In Leishmania spp. NNH hydrolyzes the
N-glycosidic bond of both purine and pyrimidine nucle-
osides to yield ribose and other bases. Upon intake and
conversion, adenine bases are irreversibly deaminated to
hypoxanthine by the enzyme adenine aminohydrolase
(AAH). However, despite its unique presence in the
parasite (w.r.t mammals and humans), the enzyme was
found to be non – essential as demonstrated by the via-
bility of Δaah knockouts [50].
Both humans and leishmania are capable of the de novo
synthesis of pyrimidines though there exists considerable
discrepancy in the organization of their correspond-
ing enzymes into multifunctional polypeptides, cellular
localization and allosteric regulators [51]. This is especially
true of the last two enzymes in the pyrimidine synthesis
pathway, orotate phosphoribosyltransferase (OPRT) and
orotidine monophosphate decarboxylase (OMPDC), which
are fused into one bifunctional protein, in both human and
parasite. However the order of the polypeptide chains are
reversed in both cases [51]. As putative OMPDCase -
OPRTase (OMPDC - OPRT) is active in the final step of
pyrimidine biosynthesis , its inhibition is expected to be
lethal for the parasite. Finally, putative deoxyuridine
triphosphatase nucleotidohydrolase (dUTPase) hydro-
lyzes dUTP to dUMP and pyrophosphate leading tothe maintenance of the dTTP:dUTP ratio in the cell
ensuring precision in DNA replication [52].
Another unique feature of protozoa belonging generally
to kinetoplastids is the compartmentalisation of the first
seven glycolytic enzymes (and therefore glycolysis) into or-
ganelles called glycosomes, in contrast to other organisms
where glycolysis generally occurs in the cytosol. This
feature is essential for the regulation of glycolysis in the
parasite and also to effectively switch over to anaerobic
forms of respiration [53]. Three such glycolytic enzymes
2,3 - bisphosphoglycerate – independent phosphoglyc-
erate mutase (PGM: 19), ATP – dependent phospho-
fructokinase (PFK: 21) and glycerol - 3 - phosphate
dehydrogenase (23), including two other enzymes either
upstream or downstream of the glycolytic pathway, pu-
tative NADP-dependent alcohol dehydrogenase (17)
and glucokinase (22) appeared in Table 1. Since glycoly-
sis is the only known source for ATP in leishmania these
enzymes offer attractive targets, especially phosphoglycer-
ate mutase (i-PGM) which is distinct in terms of structure,
catalytic mechanism and whose reduced expression was
also found to be lethal for cultured T. brucei. However,
despite intense effort on some of these validated targets
effective pharmaceutical interventions have yet to emerge.
Traditionally, drugs inhibiting folate metabolism, spe-
cifically dihydrofolate reductase (DHFR) and thymidylate
synthase (TS) have been successful as antibacterials.
DHFR maintains the THF (N5, N10-methylene tetrahy-
drofolate) pool in the cell by the NADPH dependent
reduction of dihydrofolate (DHF), which in turn is
utilized by TS to catalyze the conversion of dUMP to
dTMP. Lack of dTMP curtails DNA replication leading
to cell death [54]. In leishmania both these enzymes are
conjoined into a bifunctional enzyme DHFR-TS which is
the primary source of reduced folate and also the lone
source of thymidylate in the parasite [55]. However,
inhibition of this enzyme is ineffective in promoting
lethality due to the presence of another short chain non –
specific dehydrogenase/reductase pteridine reductase 1
(PTR 1: 2), which acts both as a modulator and bypass
for inhibitors targeting DHFR – TS. PTR 1 is responsible
for the essential salvage of unconjugated pterins (such as
biopterins) as it catalyzes the NADPH dependent two step
reduction of oxidized pterins to their active tetrahydro
forms. Deletion mutants of PTR-1 alone were non – viable
and hypersensitive to the drug methotrexate (MTX) and
had to be simultaneously inhibited [54], in case DHFR-TS
was being targeted.
Among the first 30 prioritized targets a group of pepti-
dases: peptidase m20/m25/m40 (7, 9), putative calpain –
like cysteine peptidase (14), putative serine peptidase
(16a, 16b), putative proteosome activator protein pa26
(15), putative dipeptidylcarboxypeptidase (25) and a
putative metacaspase protein (12) were found in Table 1.
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classes have been identified in the leishmanial genomes,
with L. braziliensis alone having at least 44 cysteine , 23
serine and 97 metalloproteases [56]. Of these, cysteine
proteases (CP) have been confirmed as virulence factors
playing a major role in mediating host – parasite interac-
tions; with parasites (L.tropica) treated with CP inhibitors
exhibiting reduced viability, growth and pathogenicity.
Metalloproteinases have also been known to be expressed
on the surface of Leishmania spp., protecting the patho-
gen from the defensive action of host enzymes and the
phagolysozome of macrophages [56]. In addition, a CP
inhibitor; inhibitor of cysteine peptidase (6) also appeared
at a prominent position in Table 1 by virtue of its being a
virulence factor and a probably protecting the parasite
from the hydrolytic environment of the sandfly gut or the
internal environment of host macrophages.
The rest consisted of a miscellaneous collection of
enzymes such as putative endoribonuclease L-PSP (8),
involved in mRNA salvage and protein synthesis [57];
macrophage migration inhibitory factor like protein
(13a,13b), implicated in the evasion of innate host
immunity by arresting the apoptosis of infected macro-
phages [57]; 5-methyl-tetrahydropteroyltriglutamate-
homocysteine S-methyltransferase (18), which plays
important role in the synthesis of cysteine/methionine
and also their interconversion [58], putative glutamate
dehydrogenase (27), 3-mercaptopyruvate sulfurtransferase
(30) involved in amino acid metabolism and ADF – cofilin
(20)for cellular growth and motility [57].
The protein – ligand complexes
An exhaustive literature survey was conducted to identify
inhibitors for the first thirty proteins from Table 1. In-
hibitors with experimentally determined IC50 or Ki
values were found in the literature for only 8 out of the
30 proteins. A total of 27 inhibitors (Table 2, Additional
file 3) were shortlisted for the above mentioned eight
target proteins by selecting those ligands with the lowest
IC50 values from a given family of compounds (that is a
class of compounds with a conserved backbone/kernel
and diverse peripheral substituents). Thus a total of 32
protein-ligand complexes (27 from L. major and 5 from
T. brucei, iTb4-8) were divided into three sets (Table 3;
Group A, B & C):
(I) In the first set (Group A), the crystal structures of
the ligand bound protein complexes were readily
available in the protein data bank and were uti-
lized directly for computing the structure based
pharmacophores (Table 3, Additional file 3;
inhibitors i1,i2 and i3). Henceforth the inhibitors
will be referred to by the number enumerated in
Table 2.(II) In Group B, the crystal structures of the ligand-protein
complexes were available, with the protein either
being the actual targeted molecule (from L. major)
or a closely related homologue, with sequence iden-
tity exceeding 60% with respect to the correspond-
ing protein from L. major. In the latter cases the
homologous protein present in the PDB was used
as a template to model the parasitic protein. Like-
wise, the specific ligand used to form the complex
could either be the original small molecule found
in the PDB file; or the ligand coordinates from
the crystal structure were used as a template to
add peripheral chemical groups. Specific ligands
were docked onto the corresponding parasitic
proteins using the GOLD software. In addition,
the original protein-ligand complexes present in
the PDB (from other trypanosomes) were also in-
cluded in the subsequent calculations (Table 3,
Additional file 3; inhibitors i4 – i9, iTb4 – iTb8
& i10 – i24). The ability of the docking protocol
as implemented in the GOLD software to inde-
pendently locate the ligand position as found in the
crystal structure was verified for all the complexes
used in this study.
(III) In Group C no information regarding both the
proteins and their specific ligands were available in
the PDB, though crystal structures exceeding a
sequence identity of 50% with respect to the target
were present in the database, which were used as
templates to obtain the three dimensional models of
the leishmanial proteins. The ligand coordinates
were either obtained from the PubChem database
(NCBI) or constructed ab initio (Material &
Methods) by fourth atom fixing techniques. Blind
docking (by GOLD) was used to position the
inhibitor onto the putative active site (as obtained
from the literature) of the enzyme (Table 3,
Additional file 3; inhibitors i25, i26 & i27).
Thus 32 structure based pharmacophores were com-
puted from their corresponding protein - ligand com-
plexes, of which 3 complexes belonged to Group A,
21to Group B and 3 to Group C. In addition, 5 com-
plexes (for inhibitor no. iTb4 to iTb8) whose proteins
belonged to other trypanosomatids were also included
in the calculation, by virtue of their being templates for
the leishmanial proteins in Group B.
Complexes in Group A (Table 3, Additional file 3) con-
sists of pteridine reductase 1 (PTR 1) bound to inhibitors
methotrexate (1E7W; inhibitor no. i1), trimethoprim
(2BFM; inhibitor no. i2) and 10 – propargyl-5, 8-
dideazafolic acid (2BFA; inhibitor no. i3). Crystal struc-
tures of these three complexes include the cofactor
NADPH. PTR 1 is a homotetramer, with individual
Table 2 Drug target inhibitors
No. PROTEIN Inhibitor name IC50 /Ki
i1 Pteridine Reductase 1 methotrexate (nature structural biology, volume 8,
number 6, june 2001)
1.1 μM
i2 Pteridine Reductase 1 Trimethoprim (Experimental Parasitology 87,
157–169 (1997))
12 μM
i3 Pteridine Reductase 1 10 – propargyl-5,8-dideazafolic acid (J. Mol. Biol. (2005)
352, 105–116)
> 10 μM
i4 Trypanothione Reductase methyl [(4S) - 6 - bromo - 2 - methyl - 4 - phenylquinazolin -
3(4H)-YL] acetate (J. Med. Chem. 2011, 54, 6514–6530)
6.8 μM
i5 Trypanothione Reductase (4 s) - 3 - benzyl - 6 - chloro - 2 - methyl - 4 - phenyl - 3,4 –
dihydroquinazoline (J. Med. Chem. 2011, 54, 6514–6530)
0.93 μM
i6 Trypanothione Reductase n - {2 - [(4 s) - 6 - chloro - 2 - methyl - 4 - phenylquinazolin -
3(4 h) - yl] ethyl}furan - 2 – carboxamide (J. Med. Chem. 2011,
54, 6514–6530)
0.86 μM
i7 Trypanothione Reductase (4 s) - 6 - chloro - 3 - {2 - [4 - (furan - 2 - ylcarbonyl)piperazin -
1 - yl]ethyl} -2 - methyl - 4 - phenyl - 3,4 –dihydroquinazoline
(J. Med. Chem. 2011, 54, 6514–6530)
0.42 μM
i8 Trypanothione Reductase 3 - [(4 s) - 6 - chloro - 2 - methyl - 4 - (4 - methylphenyl)
quinazolin - 3(4 h) -yl] - n,n - dimethylpropan - 1 – amine
(J. Med. Chem. 2011, 54, 6514–6530)
0.23 μM
i9 Trypanothione Reductase a C6 - substituted and C8 - substituted 3,4 - dihydroquinazoline
analogue (J. Med. Chem. 2011, 54, 6514–6530)
0.35 μM
i10 Pteridine Reductase 1 a quinazoline derivative (Experimental Parasitology 1997, 87,
157–169 )
0.4 μM
i11 Pteridine Reductase 1 a 2,4-Diaminopyrimidine derivative (Experimental Parasitology
1997 ,87, 157–169 )
0.4 μM
iTb4 to iTb8 Trypanothione Reductase crystal complex
from T. brucei
Above inhibitor i1 to i5. (J. Med. Chem. 2011, 54, 6514–6530) Same as above
i12 ATP dependent Phospho Fructo Kinase a N, N0 - substituted - 1-amino - 2, 5 - anhydro - 1 - deoxy -
1 - D -mannonamide derivatives (Bioorg. Med. Chem. 2008,
16 , 5050–5061)
49 μM
i13 ATP dependent Phospho Fructo Kinase 2, 5 - anhydro - 1 - deoxy - 1 - (3, 4 - dichlorobenzylamino) -
D – mannitol (Bioorg. Med. Chem. 2008, 16 , 5050–5061)
0.4 μM
i14 ATP dependent Phospho Fructo Kinase 2, 5 - Anhydro - 1 - deoxy - 1 - (3, 4 - dichlorobenzylamino) -
D - 3, 4 - dichlorobenzylmannonamide (Bioorg. Med. Chem.









a 5′ - Ph3CNH derivative (J. Med. Chem. 2005, 48, 5942–5954) NA; substrate analog
i17 Deoxyuridine Triphosphate
Nucleotidohydrolase
5′ - tritylamino - 3′ - fluoro - 2′, 3′, 5′ – trideoxyuridine (J. Med.




5′ - O - triphenylsilyl - 2′, 3′ - didehydro - 2′, 3′ – dideoxyuridine
(J. Med. Chem. 2005, 48, 5942–5954)
12 μM
i19 Nonspecific Nucleoside Hydrolase immucillin A (J. Biol. Chem. 1999,274(30, 21114–21120) 15 nM
i20 Nonspecific Nucleoside Hydrolase immucilin ACAP (J. Biol. Chem.1999, 274(30), 21114–21120) 6.5 nM
i21 Nonspecific Nucleoside Hydrolase N - (9 - deaza - adenin - 9 - yl) methyl - 1, 4 - dideoxy - 1, 4 -
imino - D - ribitol (Antimicrobial Agents and Chemotherapy,
2010, 1900–1908)
0.49 μM
i22 Nonspecific Nucleoside Hydrolase immucillin-H (1, 4 - dideoxy - 4 - aza - 1 - (s) - (9 - deazahypoxanthin -
9 - yl) - d - ribitol) (Biochem Biophys. Acta.2009, 1794, 953–960)
Ki = 6.2 nM
i23 Nonspecific Nucleoside Hydrolase 7 - (((2R, 3R, 4S) - 3, 4 - dihydroxy - 2 - (hydroxymethyl) pyrrolidin -
1 - yl) methyl) - 3H - pyrrolo [3, 2-d] pyrimidin - 4 (5H) - one
(Biochem Biophys. Acta. 2009, 1794 , 953–960)
Ki = 4.4 nM
i24 Nonspecific Nucleoside Hydrolase (2R, 3R, 4S) - 2 - (hydroxymethyl) - 1 - (quinolin - 8 - ylmethyl)
pyrrolidine - 3, 4 – diol (Biochem Biophys. Acta. 2009, 1794, 953–960)
Ki = 10.8 μM
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Table 2 Drug target inhibitors (Continued)
i25 Trypanothione Synthetase 1-[3-(3-fluorophenyl)indazol-1-yl]-3,3-dimethylbutan-2-one
(J.Biol.Chem., 2009, 284( 52), pp. 36137–36145)
0.095 μM
i26 Putative-UDP-glc-4′-epimerase ebselen (Bioorg. & Med. Chem. Lett. 2006, 16 , 5744–5747) 0.62 μM
i27 GLO1 S-4-bromobenzylglutathionylspermidine (Molecular Microbiology,
2006, 59, 1239–1248)
Ki = 0.54 μM
Inhibitors identified for eight of the proteins from Table 1 along with their respective IC50’s or Ki values with respect to their corresponding target proteins. The
inhibitors will be referred to by the numbers assigned in the first column.
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of a central 7 - stranded parallel β-sheet with three
α-helices on either side (Figure 2) [54]. All three
structures exhibit high structural conservation, with the
active site being an elongated L-shaped cleft constituted
by the C terminal section of the strands β1 - β6, parts of
the helices α1, α4 and a loop interconnecting a strand (β6)
and a helix (α6) [54]. Two more complexes involving
PTR1 with a quinazoline derivative (inhibitor no. i10) and
a 2, 4-diaminopyrimidine derivative (inhibitor no. i11)
were included in Group B. The methotrexate structure
from the PDB file 1E7W was used as a template to build
the quinazoline derivative (inhibitor no. i10) and the best
solution with a CHEMPLP score of 49.44 was finally se-
lected out of several GOLD runs (See Methods). The rmsd
between the atoms common to methotrexate (pteridine
ring or its derivative) as located in the PTR1 active site
and the docked inhibitor-i10 was 0.77 Å. Protein ligand
contacts involving residues Ser 111, Phe 113, Asp 181,
Leu 188, Tyr 194, Leu 226 , Leu 229, Asp 232 and Met
233 were common both for methotrexate and Inhibitor
i10 (Additional file 4). Notably, contacts between the pter-
idine ring and Phe 113, Ser 111 were prominent in both
cases. Additional contacts were observed in methotrexate
with respect to the inhibitor due to the more elongated
character of the molecule, extending from the pteridine
ring (Additional file 4; Figure 2). A similar procedureTable 3 Protein – inhibitor groups
Groups Status considered
A Protein-inhibitor complex structure available
Modelling not required for protein
Inhibitor’s position and coordinates known
Docking not necessary
B Protein-inhibitor complexes not available
Modelling required for protein from close homolog or struct
Inhibitor pose & coordinates taken from known homologous
Docking performed with positioned ligand
C Protein-inhibitor complex not available
Modelling required for protein from close homolog
Inhibitors are drawn ab initio and energy minimized
Blind docking performed based on the putative active site foadopted for inhibitor-i11 based on trimethoprim (PDB code
2BFM) as a template gave a corresponding CHEMPLP
score of 79.80. Although the orientations for both ligands
were fairly similar, a translational shift in the position of
inhibitor i11 was due to the substitution of -CH2Ph in
place of -H in the pyrimidine ring of trimethoprim. The
common residual contacts for both ligands were Phe 113,
Asp 181, Leu 188, Tyr 194, Leu 226, Leu 229, and His 241
(Additional file 4). All the four ligands also maintained
atomic contacts with NADPH.
Other protein targets in Group B apart from PTR – 1
were TR, PFK, dUTPase and NNH. Five complexes of
TR from T. brucei were included (inhibitor numbers
iTb4 – iTb8; See Table 2, Additional file 4) directly from
the crystal structures with PDB codes 2WP5, 2WP6,
2WPE, 2WPC and 2WPF [59]. TR from T. brucei has a
sequence identity of 66.5% with respect to the correspond-
ing protein from L. major and was used as a template to
model the parasitic protein. TR (T. brucei) is a homodimer
with each subunit consisting of three domains, the in-
hibitor binding cleft being formed by a congregation of
α helices in domain I [60]. The binding site exhibits
conformational flexibity indicating an induced fit of
the ligand to the binding pocket. Thus for each ligand
(i4 – i8) the leishmanial protein was repeatedly modeled
from its original complex (2WP5, 2WP6 etc. as the case
maybe). The ligands were initially placed in the active siteProteins
PTR I





und in the literature
Figure 2 Active site of Pteridine Reductase 1 (PTR1) complexed
with methotrexate (i1 - blue) as found in the crystal structure
IE7W and the docked quinazoline derivative (i10 – red).
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and translation vectors obtained upon superposing the Cα
coordinates (Dali server; http://ekhidna.biocenter.helsinki.
fi/dali_lite/start) of the template onto its associated model.
Subsequent GOLD runs gave high CHEMPLP scores
greater than 60.0 for all the five complexes and rmsd’s
ranging from 0.2 – 0.8 Å between the final docked struc-
ture and the initial position of the ligand in the modeled
protein (Figure 3).
The active sites for all the five ligands (from 2WP5 –
2WPF) were completely conserved in both L . major and
T. brucei , with residues Leu 17, Glu 18, Trp 21, Tyr 110,
Met 113, Phe 114 making atomic contacts with all the
ligands (with the exception of inhibitor i9 in L. major), in
both the enzymes (Additional file 4). In addition, Ser
14, Leu 17, Gly 49, Leu 120 and Ile 339 were found in
the vicinity of the ligands, occasionally in some of the
complexes. i9 (Table 2, Additional file 4) was obtainedFigure 3 Active site of the modeled Trypanothione Reductase (TR) fro
placed utilizing the superposition matrices and vectors obtained fromfrom (4 s)-3-benzyl-6-chloro-2-methyl-4-phenyl-3,4-
dihydroquinazoline (inhibitor i8:2WP6) and the final
docked position (allowing for flexibility in residues Glu
18, Trp 21 and Met 113 in the active site) had a rmsd
of 0.66 Å (with respect to common atoms of 3,4-dihy-
dro-quinazoline analogues) and a score of 34.69. The
same set of core residues (Leu 17, Glu 18 etc.) includ-
ing Ser 14 and Leu 120 also formed the active site for
inhibitor i9 (Additional file 4).
The active site for fructose-6-phosphate (F6P) of the
trypanosomatid ATP dependent PFK from T. brucei
exhibits significant structural differences compared to its
human counterpart and is located at the interface of two
subunits in the homotetramer. Each subunit is com-
posed of three domains (A, B, C) with the ATP binding
site (between domains B and C) lying adjacent to the
F6P site [61]. The complete tetramer of PFK from L.
major was modeled based on the homologous protein
from T. brucei (3F5M) with respect to which it shares a
71% sequence identity and ATP (along with the Mg2+ )
were docked/placed in the model, prior to placement of
the substrate. The crystal structure of PFK from T. brucei
in 3F5M is in complex with ATP and does not contain the
substrate F6P, whose coordinates were extracted from
1MTO which consists of PFK from B. stearothermophilus
in complex with F6P [61] and docked onto the corre-
sponding active site in leishmanial PFK, subsequent to ini-
tial positioning of the molecule, following similar methods
given above. Beginning with the coordinates of the furan
ring of F6P, three other inhibitors were built by making
appropriate substitutions : a N,N0-substituted-1-amino-2,
5-anhydro-1-deoxy-1- D-mannonamide derivative (inhibi-
tor no. i12); 2,5-anhydro-1-deoxy-1-(3,4-dichlorobenzyla-
mino) -D-mannitol (inhibitor no. i13) and 2,5-Anhydro-1-
deoxy-1-(3,4-dichlorobenzylamino)-D-3,4-dichlorobenzyl-
mannonamide (i14). Subsequent docking with GOLD on
a rigid active site gave CHEMPLP scores 70.35, 67.80 andm L. major complexed with ligand i4 (red) along with iTb4 (blue)
superposing the protein model onto its template (2WP5).
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peated attempts to dock the ligands on a flexible site did
not yield physically meaningful results. The only common
feature between the inhibitors – i12, i13 and i14 was the
furan ring (from F6P) and considerable variability in the
remaining features tended to shift the ligands from their
initial position depending on the length and chemical
character of the substituents on either side of the furan
ring. Consequently with a few exceptions, the constella-
tion of residues constituting their binding pockets were
significantly different (Additional file 4).
The crystal structure of dUTPase from L. major, is a
dimeric all α protein (in contrast to its trimeric all β
human homologue) was obtained from the PDB (2CJE)
[62]. The active site is located in the vicinity of the
interface between the rigid and mobile domains which
constitute each subunit [62]. In addition, the site on
one subunit is also constituted by a loop contributed
by the other monomer. Crystal structures of the closed
and open forms of the enzyme from T. cruzi revealed a
significant movement of the mobile domain and re-
arrangement of the secondary structural elements [62].
The closed ligand bound form of dUTPase from 2CJE
was used to model complexes with three other inhibitors.
Since the enzyme sits in a special position in the crystal
structure, the entire dimer of dUTPase was generated prior
to the placement of the other ligands. The bound substrate
analogue DUPNHP (2′-deoxyuridine 5′-alpha,beta-imido-
diphosphate from 2CJE) was used to design the three inhib-




(i18). CHEMPLP scores for all the four inhibitors
ranged from 90–100 and the rmsd’s between the start-
ing and final docked position ranged from 0.5 – 1.2 Å.
Based on the visual examination of the initial ligand
position in the active site of the enzyme and survey of
the ligand – protein atomic contacts, selected residues
were rendered flexible in the docking process which
could provide steric hindrance to the optimal orienta-
tion of the ligand or adopt alternative conformations in
the binding pocket (inhibitor i15 - flexible residues
Asn25, Glu48, Glu51, Glu76 , Tyr191 ; inhibitor- i17 :
Asn25, Glu51 , Tyr 191; inhibitor- i18 : Glu48, Glu51,
Glu76 and Tyr191).
For NNH (Nonspecific Nucleoside Hydrolase) six inhib-
itors (inhibitor no. i19 to i24) were chosen for docking.
Complexes of three of these inhibitors (i22, i23, i24) with
a homologous protein from T. vivax were available in the
PDB (2FF2, 3EPW and 3EPX respectively), whereas the
uncomplexed individual structure of NNH from L. major
was found in 1EZR. The α|β enzyme from L. major is a
homotetramer with an indispensable calcium ion in itsactive site [63]. Coordinates for the inhibitors i19, i20 were
built starting from the pyrimidine group in the structure
of immucilin – H present in 2FF2 and inhibitor i21from
the ligand (i23) present in 3EPW. Docking of these in-
hibitors in the active site of the protein (including the
Ca2+ ion), exhibited CHEMPLP scores and rmsd’s
(with respect to their original placement) ranging from
50 – 60 and 1.2 – 1.6 Å, respectively. Flexibility was
allowed for residues Phe167 and His240 in the enzyme
active site during the docking process for all ligands
associated with this protein. Interactions with residues
Asp 15, Asp 14 (with the exception Inhibitor – i22),
Thr 126, Met 152 (except Inhibitor – i20) Asn 160, Glu
166, Phe 167, Asn 168, His 240 , Asp 241 and the
calcium ion were common to all the ligands. Contacts
with Leu 191 were found only for Inhibitors – i19 and
i22 (Additional file 4).
Group C
Due to the lack of available prototypes or templates in
terms of actual crystal structures depicting the position
of the ligands in their binding sites, the confidence level
associated with the docked complexes in Group C is
necessarily low and thus the discussion of these complexes
will be fairly brief. The crystal structure trypanothione
sythetase (TS) from L. major (2VOB) has three puta-
tive binding sites for ATP, spermidine and glutathione
(GSH). Inhibitor-7 (1-[3-(3-fluorophenyl) indazol-1-yl]-3,
3-dimethylbutan-2-one) binds with uncompetitive inhib-
ition for both the putative ATP and GSH binding sites
whereas exhibits competitive inhibition for the site associ-
ated with spermidine. Thus, the inhibitor (i25) was placed
at the centroid of this site constituted by residues Arg 613,
Arg 328, Ser 351, Glu 355, Phe 249 and Glu 407. As
mentioned previously, inhibitor – i25 was constructed
by ab initio fourth atom fixing techniques coupled to
energy minimization. Several iterations with flexible
ligand and rigid side chains of the active site led to a
final CHEMPLP score of 47.32. Introduction of side
chain flexibility did not appear to improve final docking
poses. Likewise, inhibitor – i26 (ebselen) was positioned
in the putative UDP binding pocket of UDP-glc-4′-epim-
erase (GalE) of L. major based on the centroid of residues
R335, R268, N202 and H221. GalE from L. major was
modeled based on the homologous enzyme from T. brucei
(~58% sequence identity : 1GY8). Coordinates of ebselen
were built by the same methods mentioned above and the
final docked position had a CHEMPLP score of 36.96.
The crystal structure of glyoxalase-I (GLO I) from
L. major was obtained from 2C21 [44] and S-4-
bromobenzylglutathionylspermidine (inhibitor-i27) was
docked into the putative active site of the enzyme consti-
tuted by residues : A chain - His8, Arg12, Arg33, Trp35,
Val37, Glu52, Glu59, Asn63 and B chain - His77, Asp100,
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Lys130. The CHEMPLP docking score of 79.43 was ob-
tained for this docking. For all docking runs in case of i27
both the energy minimized ligand and the residues com-
posing the protein active site were held rigid, as additional
trials with either flexible ligands and/or side chains led to
significant shifts in their position away from the putative
binding sites. As mentioned previously the confidence
level is relatively low for these complexes.
Pharmacophore design and screening of zinc database
34 structure based pharmacophores were derived from
their corresponding ligand bound three dimensional struc-
tures using LigandScout version 3.12 (build 20130912).
Those pharmacophores whose area under the ROC curve
(See Methods), were less than 0.75 whilst validation,
were filtered out (i8, i11, i17 and i20). In addition, phar-
macophores with either too few (i2, i20, i26: 3 features)
or too many features (i14:13 features, i16:16, i27:12)
were removed, leaving a total of 23 pharmacophores for
subsequent calculations (Table 4). These pharmacophores
were used to search the ZINC database using ZINCPhar-
mer (html search engine) with parameters: ‘Max Hits per
Conf ’ = 1, ‘Max Hits per Mol’ = 1, ‘Max Total Hits’ = 20
and ‘Max RMSD’ = 0.5, 0.75, 1. The Max RMSD was grad-
ually increased only if no hits were recorded in the initial
cutoffs. The topmost hit of every pharmacophore with the
least RMSD, along with hits which were similar to ap-
proved drugs (generally greater than 90%) are shown in
Table 4 and all the hits are given in Additional file 5.A
total number of 344 hits were recorded from the ZINC
database which were then used to search the Drug Bank
(http://www.drugbank.ca) with a cutoff in similarity score
set to 70%, so as to identify similar molecules actually in
use as pharmaceutical products. From the 344 compounds
distributed over 23 pharmacophores, 9 exhibited similar-
ities to drugs under investigation, 319 showed similarities
to experimental drugs (known to bind to specific proteins
in mammals, bacteria, viruses, fungi, or parasites) and 16
were similar to approved drugs (in at least one country).
Of these 344 hits, 40 were from complexes in Group A,
304 from Group B and none from Group C.
The structure based pharmacophore derived from
methotrexate (i1) bound to pteridine reductase returned
20 small molecule compounds (Additional file 5) from
the ZINC database, with the pteridine ring being the
principal pharmacophoric feature. Most of these com-
pounds from ZINC were variable chemical substitutions
around the pteridine ring. Inhibitor i2, i10 and i11 (all
complexed with pteridine reductase) failed to give any
hit whereas the pharmacophore corresponding to i3 –
pteridine reductase, again returned 20 compounds.
Two approved drugs pralatrexate and triamterene were
found to be similar to hits from pharmacophores involvingi1 and i3 (Table 5). Pharmacophores from inhibitors i4,i5,i6,
i7,i8,i9 complexed with trypanothione reductase found
20,4,20,20,20 compounds from the ZINC database respect-
ively. For most of these compounds the phenyl ring and
the terminal carboxyl (for example in i4 - methyl [(4S) -
6 - bromo - 2 - methyl - 4 - phenylquinazolin - 3(4H)-YL]
acetate) appeared to be crucial pharmacophoric features.
The approved drug primaquine was found to be similar to
the compound ZINC01600860 corresponding to i7. Inhib-
itors i12 (2 hits), i13 (20 hits) and i14( 0 hit) complexed
with parasitic phosphofructokinase failed to find any
approved drug from Drugbank, whereas lidocaine and
tocainide were found to be similar to ZINC29396021
(i18). For inhibitors i15 (6 hits), i16 (0),i17(0) and i18(20)
complexed with deoxy uridine triphosphatase nucleotide
hydrolase, the principal pharamacophoric feature(s) re-
sponsible for the hits appeared to be the uridyl moiety
coupled to the pentose sugar ring. Especially, fruitful were
pharmacophores due to complexes with nonspecific nu-
cleoside hydrolase as they yielded acarbose (i19 – 5 hits);
mannitol, calcium gluceptate, nelarbine, didanosine,
vidarbine (i21 – 20 hits); kanamycin, tobramycin, neomy-
cin, framycetin, paromomycin, gentamicin, glucosamine,
netilimicin (i22 – 20 hits); pitavastatin (i23 – 20 hits) and
diphylline (i24 – 20 hits). In this case the essential phar-
macophoric recognition features were the pyrimidine ring
coupled to a pentose sugar. Of the remaining pharmaco-
phores from i25 (20 hits), i26(0),i27(0) complexed with
trypanothione synthetase no drug could be recovered
from DrugBank. The information with regard to the list of
approved drugs has been summarized in Table 5.
Interestingly, the search for approved drugs similar to
ZINC compounds led to paromomycin (with a similarity
score of 0.944 with respect to immucilin H in complex
with nonspecific nucleoside hydrolase, i22)spontaneously
appearing in the list, a drug having passed all clinical tri-
als and is now currently being prescribed for visceral
leishmaniasis. Paromomycin has also been successfully
used in topical creams for the treatment ulcerative cuta-
neous leishmaniasis [64]. The inclusion of paromomycin
provides some confidence that some of the listed drugs
(in Table 5) could possibly exhibit some measure of
antileishmanial activity. Likewise framycetin, neomycin,
gentamicin, netilimicin and tobramycin all belong to the
same class of aminoglycoside antibiotics generally known
to inhibit protein synthesis. Framycetin and neomycin
have found extensive use in topical ointments and creams.
Didanosine and vidarbine are antiviral drugs the former
being a nucleoside analogue of guanosine with hypoxan-
thine attached to the sugar ring and the latter an analogue
of adenosine, in this case D – arabinose replacing D-ribose.
Nelarabine on the other hand is a purine nucleoside
analogue currently being applied in the chemotherapy of
T-cell acute lymphoblastic leukemia. Other drugs include









SMILES of topmost hit ZINCID
i1 9 2 0.97 C/C2 = N/C = 1/N = C(/N)N = C(N)C = 1/N = C2/C = 3C = CC([Cl]) = C([Cl])C = 3 ZINC34515729
C#CC[C@@](CC = 2C = NC1 = NC(N) = NC(N) = C1N = 2)(C = 3C = CC(=CC = 3)C([O-]) = O)C([O-]) = O ZINC22012802
C#CC[C@](CC = 2C = NC1 = NC(N) = NC(N) = C1N = 2)(C = 3C = CC(=CC = 3)C([O-]) = O)C([O-]) = O ZINC22012807
CC = 1C = CC = C(C = 1)C2 = NC = 3C(/N = C2/N) = NC(N) = NC = 3 N ZINC01566881
C#CC[C@]([H])(CC = 2C = NC1 = NC(N) = NC(N) = C1N = 2)C = 3C = CC(=CC = 3)C([O-]) = O ZINC22012811
C#CC[C@@]([H])(CC = 2C = NC1 = NC(N) = NC(N) = C1N = 2)C = 3C = CC(=CC = 3)C([O-]) = O ZINC22012815
i3 8 3 0.88 CC = 1C = CC = CC = 1NC(=O)C = 3[S]C = 2/N = C(/N)C(C#N) = CC = 2C = 3 N ZINC18240380
C#CC[C@@]([H])(CC = 2C = NC1 = NC(N) = NC(N) = C1N = 2)C = 3C = CC(=CC = 3)C([O-]) = O ZINC22012815
i4 6 1 0.97 CN(C)C = [N+]C(=[S])NC = 1C = CC([F]) = CC = 1 ZINC03028809
i5 7 2 0.97 CC = 1/C = C(/C)N = C(N = 1)N/C(=N\C(=[S])NC = 2/C = C(/OC)C([Cl]) = CC = 2OC)N3CCC[C@@](C)([H])C3 ZINC14160212
i6 6 1 0.97 CN(C)C = 1[N+] = CC = CC = 1CNC(N[C@@]2([H])CC[C@@]([H])(C2)[S]C) = [N+]C ZINC72776752
i7 5 1 0.9 COC = 1C = CC(=CC = 1NC(=[S])NC = 2C = CC([F]) = CC = 2)[N+]([O-]) = O ZINC00493353
C/C1 = C/C = NC = 2C1 = CC(=CC = 2 N[C@@](C)([H])CCC[N+]CCC)OC ZINC01600860
i9 6 1 0.97 CN(C)C = [N+]C(=[S])NC = 1C = CC([F]) = CC = 1 ZINC03028809
iTb4 6 1 0.97 CN(C)C = [N+]C(=[S])NC = 1C = CC([F]) = CC = 1 ZINC03028809
iTb5 7 2 0.99 CC = 1/C = C(/C)N = C(N = 1)N/C(=N\C(=[S])NC = 2/C = C(/OC)C([Cl]) = CC = 2OC)N3CCC[C@@](C)([H])C3 ZINC14160212
iTb6 7 2 0.98 CC = 1/C = C(/C)N = C(N = 1)N/C(=N/C(=[S])NC = 2C = CC([F]) = CC = 2)NCC = 3C = CC([F]) = CC = 3 ZINC14156881
iTb7 5 1 0.9 C/C1 = C(/C(=NN1C[C@@]2([H])CCC[N+]2C)C([F])([F])[F])C(=O)NCCC[N+](C)C ZINC49362845
C/C1 = C/C = NC = 2C1 = CC(=CC = 2 N[C@@](C)([H])CCC[N+]CCC)OC ZINC01600860
iTb8 8 3 0.99 CC = 1/C = C(/C)N = C(N = 1)N/C(=N\C(=[S])NC = 2/C = C(/OC)C([Cl]) = CC = 2OC)N3CCC[C@](C)([H])C3 ZINC14160209
i10 7 2 0.91 C/C2 = C/C1 = N/N = C(/[S]CCCCCO)N1C(C) = N2 ZINC72058109
i12 7 3 0.97 CC(=O)NC = 4C = 1/C = C(/[F])C = CC = 1N3C[C@](C)(C(=O)N[C@@]2([H])CCCC2)N(CC[N+](CC)CC)C
(=O)C3 = 4
ZINC21866480
i13 4 1 0.99 CC = 1C = CC(=CC = 1)C[N+]2CCC([H])(CC2)CC(N) = O ZINC40540751
i15 5 2 0.78 C[C@@]1([H])CN(C[C@@](C)([H])O1)[C@]([H])(C(=O)NC = 2C = CC(=CC = 2)NC(=O)COC)C(C)(C)[H] ZINC58203407
i18 4 1 0.76 C[C@@]1([H])C[C@]([H])(CC)N(C1)C(=O)CC[C@@]2([H])NC(=O)NC2 = O ZINC73336547
CC = 1C = C/C = C(/C)C = 1NC(=O)CNC = 2C = CC = C(C = 2)NC(C) = O ZINC29396021



























Table 4 Results from searching the ZINC Database using structure based pharmacophores (Continued)
C[C@](O)([H])[C@](O)([H])[C@@](O)([H])[C@@](O)([H])CO ZINC03872643
CC(=O)C(=O)[C@@](O)([H])[C@](O)([H])[C@@](O)([H])[C@@](O)([H])CO ZINC64219378
CN/C2 = N/C1 = C(/N = C(/N)NC1 = O)N2[C@]3([H])O[C@]([H])(CO)[C@](O)([H])[C@]3(O)[H] ZINC13361972










i23 7 2 0.87 OC = 1C = C/C(=C(/O)C = 1)C2 = NN/C(=C2/C4 = N/C = 3C = CC = CC = 3[S]4)C([F])([F])[F] ZINC04126006
[O-]C(=O)C[C@](O)([H])C[C@](O)([H])C = CC = 2C(=C1C = CC = CC1 = NC = 2[C@]3([H])CC3)C = 4C = CC
([F]) = CC = 4
ZINC11616582
i24 7 2 0.87 CC = 1C(O) = CC = C(C = 1O)C2 = NN = C[C@@]2([H])C4 = NC = 3C = CC = CC = 3[S]4 ZINC18188334
CN2C = 1/N = C(/NCCO)N(CCO)C = 1C(=O)NC2 = O ZINC01876281
i25 6 2 0.8 CC = 1C = CC(=CC = 1)CN2C(=O)C(=CNC2 = O)CC([O-]) = O ZINC20156415
The topmost hits from the ZINC database utilizing the pharmacophores from the protein – inhibitor complexes. For each pharmacophore the area under the ROC curve and the number of omitted pharmacophoric




















Table 5 Approved drugs similar to hits in the ZINC database
Protein Inhibitor ZINC code Approved drug (drug bank code) Similarity score
Pteridine i1 ZINC34515729 Triamterene (DB00384) 0.78
Reductase 1 i1 ZINC01566881 “ 0.96
i1 ZINC22012802 Pralatrexate (DB06813) 0.73
i1 ZINC22012807 “ 0.73
i1 ZINC22012811 “ 0.75
i1,i3 ZINC22012815 “ 0.75
Trypanothione Reductase i7 ZINC01600860 Primaquine (DB01087) 0.84
Deoxyuridine i18 ZINC29396021 Lidocaine (DB00281) 0.80
Triphosphatase Nucleotido hydrolase ZINC29396021 Tocainide (DB01056) 0.72
Nonspecific i19 ZINC77302460 Acarbose (DB00284) 0.98
Nucleoside i21 ZINC03872643 Mannitol (DB00742) 1.0
Hydrolase i21 ZINC64219378 CalciumGluceptate (DB00326) 0.70
i21 ZINC13361972 Nelarabine (DB01280) 0.76
i21 ZINC13361972 Didanosine (DB00900) 0.76
i21 ZINC13361972 Vidarabine (DB00194) 0.76
i22 ZINC08214767 Kanamycin (DB01172) 1.0
i22 ZINC43758958 “ 0.85
i22 ZINC08214767 Tobramycin (DB00684) 0.96
i22 ZINC43758958 “ 0.88
i22 ZINC08214767 Neomycin (Db00094) 0.94
i22 ZINC43758958 “ 0.88
i22 ZINC08214767 Framycetin (DB00452) 0.94
i22 ZINC43758958 “ 0.88
i22 ZINC08214767 Paromomycin (DB01421) 0.94
i22 ZINC43758958 “ 0.88
i22 ZINC08214767 Gentamicin (DB00798) 0.76
i22 ZINC70672630 “ 0.77
i22 ZINC08214767 Glucosamine(DN01296) 0.74
i22 ZINC43758958 “ 0.88
i22 ZINC70672630 Netilmicin (DB00955) 0.71
i23 ZINC11616582 Pitavastatin (DB08860) 1.0
i24 ZINC01876281 Dyphylline (DB00651) 0.71
Approved drugs with similarity score greater than 0.70 to specific ZINC hits. Information of the protein – inhibitor complex corresponding to the pharmacophore
is also given.
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http://www.biomedcentral.com/1756-0500/7/802lidocaine (and its analog tocainide) an amino amide
type local anesthetic , primaquine a member of the 8 –
aminoquinoline group of drugs used in the treatment
of malaria/ pneumocystis pneumonia, pralatrexate an
anti-folate for anti-cancer therapy and triamterene a
diuretic drug for hypertension. Notably, pteridine reductase,
trypanothione reductase, deoxyuridine triphosphatase have
been found to be essential for survival and nonspecific nu-
cleoside hydrolase plays a central role in the purine salvage
pathway. Currently, our aim is to experimentally test the
anti – leishmanial character of these compounds/approved
drugs.Conclusions
The work reported in this paper demonstrates the series
of computational steps beginning with the comparison
of genomes, prioritization of prospective drug targets,
culling or assembly of inhibitor – target complexes
through template based model building and docking,
generation of pharmacophores and their subsequent use
for searching small molecule databases (such ZINC/Drug
Bank), to rationally assemble a set of lead compounds for
experimentally testing as potential antileishmanials. The
natural appearance of paromomycin, a drug currently
being employed against visceral leishmaniais, in the list of
Waugh et al. BMC Research Notes 2014, 7:802 Page 19 of 21
http://www.biomedcentral.com/1756-0500/7/802lead compounds lends some confidence to the adoption of
such scaffold – hopping techniques in order to generate a
library of prospective antileishmanials. The next stage of
the work will involve experimental validation of these
leads.
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